Recro Pharma Inc (REPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Recro Pharma Inc (Recro Pharma) is a specialty pharmaceutical company that focuses on developing novel products for commercialization in hospital and other acute care settings and provides contract development and manufacturing (CDMO) services. The company is developing IV/IM Meloxicam, a proprietary, rapid-onset, long-acting preferential COX-2 inhibitor for the treatment of acute post-operative pain and acute pain; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine for the treatment of peri-procedural pain and cancer breakthrough pain. It also develops and manufactures pharmaceutical products based on its proprietary delivery technologies for commercial partners. Recro Pharma is headquartered in Malvern, Pennsylvania, the US.
Recro Pharma Inc Key Recent Developments
May 09,2018: Recro Pharma Reports First Quarter 2018 Financial Results
May 02,2018: Recro Pharma Announces Commercial Team Additions
Mar 29,2018: Recro Pharma Announces Commercial Team Additions
Mar 02,2018: Recro Pharma Announces Commercial Team Additions
Feb 27,2018: Recro Pharma Announces Year End 2017 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
'
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Recro Pharma Inc - Key Facts 6
Recro Pharma Inc - Key Employees 7
Recro Pharma Inc - Key Employee Biographies 8
Recro Pharma Inc - Major Products and Services 10
Recro Pharma Inc - History 11
Recro Pharma Inc - Company Statement 12
Recro Pharma Inc - Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
Company Overview 15
Recro Pharma Inc - Business Description 16
Business Segment: Acute Care 16
Overview 16
Business Segment: Contract Development and Manufacturing 16
Overview 16
Performance 16
R&D Overview 16
Recro Pharma Inc - Corporate Strategy 17
Recro Pharma Inc - SWOT Analysis 18
SWOT Analysis - Overview 18
Recro Pharma Inc - Strengths 18
Recro Pharma Inc - Weaknesses 19
Recro Pharma Inc - Opportunities 20
Recro Pharma Inc - Threats 21
Recro Pharma Inc - Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios - Capital Market Ratios 23
Financial Ratios - Annual Ratios 24
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
Recro Pharma Inc, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
May 09, 2018: Recro Pharma Reports First Quarter 2018 Financial Results 33
May 02, 2018: Recro Pharma Announces Commercial Team Additions 35
Mar 29, 2018: Recro Pharma Announces Commercial Team Additions 36
Mar 02, 2018: Recro Pharma Announces Commercial Team Additions 37
Feb 02, 2018: Recro Pharma Announces Key Sales Team Additions 38
Nov 20, 2017: Recro Pharma Secures $100M Credit Facility 39
Nov 09, 2017: Recro Pharma Reports Third Quarter 2017 Financial Results 40
Aug 21, 2017: Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development 42
Aug 10, 2017: Recro Pharma Reports Second Quarter 2017 Financial Results 43
Jun 16, 2017: Recro Pharma to Participate in Hospital Drug Launch Panel at the JMP Life Sciences Conference 45
Section 6 – Appendix 46
Methodology 46
Ratio Definitions 46
About GlobalData 50
Contact Us 50
Disclaimer 50
List of Tables
Recro Pharma Inc, Key Facts 6
Recro Pharma Inc, Key Employees 7
Recro Pharma Inc, Key Employee Biographies 8
Recro Pharma Inc, Major Products and Services 10
Recro Pharma Inc, History 11
Recro Pharma Inc, Subsidiaries 14
Recro Pharma Inc, Key Competitors 22
Recro Pharma Inc, Ratios based on current share price 23
Recro Pharma Inc, Annual Ratios 24
Recro Pharma Inc, Annual Ratios (Cont...1) 25
Recro Pharma Inc, Annual Ratios (Cont...2) 26
Recro Pharma Inc, Interim Ratios 28
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
Recro Pharma Inc, Recent Deals Summary 32
Currency Codes 46
Capital Market Ratios 46
Equity Ratios 47
Profitability Ratios 47
Cost Ratios 48
Liquidity Ratios 48
Leverage Ratios 49
Efficiency Ratios 49
List of Figures
Recro Pharma Inc, Performance Chart (2013 - 2017) 27
Recro Pharma Inc, Ratio Charts 29
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31